Lack of Neuroprotective Effects of High-Density Lipoprotein Therapy in Stroke under Acute Hyperglycemic Conditions.
David CouretCynthia PlanesseJessica PatcheNicolas DiotelBrice NativelSteeve BouraneOlivier MeilhacPublished in: Molecules (Basel, Switzerland) (2021)
Intraperitoneal D-glucose injection allowed HDL- and saline-treated groups to reach a blood glucose level of 300 mg/dl in the acute phase of cerebral ischemia. HDL injection did not significantly reduce mortality (19% versus 29% in the saline-injected group) or cerebral infarct size (p = 0.25). Hemorrhagic transformations and inflammation parameters were not different between the two groups. In addition, HDL did not inhibit apoptosis under acute hyperglycemic conditions. Conclusion: We observed a nonsignificant decrease in cerebral infarct size in the HDL group. The deleterious consequences of reperfusion such as hemorrhagic transformation or inflammation were not improved by HDL infusion. In acute hyperglycemia, HDLs are not potent enough to counteract the adverse effects of hyperglycemia. The addition of antioxidants to therapeutic HDLs could improve their neuroprotective capacity.
Keyphrases
- cerebral ischemia
- subarachnoid hemorrhage
- blood glucose
- liver failure
- brain injury
- blood brain barrier
- oxidative stress
- high density
- respiratory failure
- acute myocardial infarction
- aortic dissection
- stem cells
- diabetic rats
- metabolic syndrome
- ultrasound guided
- type diabetes
- emergency department
- risk factors
- hepatitis b virus
- glycemic control
- cardiovascular disease
- adipose tissue
- endoplasmic reticulum stress
- bone marrow
- cell cycle arrest
- signaling pathway
- acute coronary syndrome
- left ventricular
- acute respiratory distress syndrome
- pi k akt